{
    "id": "5c6b7a9e7c78d69471000029",
    "question": "Is cabozantinib effective for Hepatocellular Carcinoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To determine if cabozantinib is effective for Hepatocellular Carcinoma (HCC), we need to consider its mechanism of action and clinical trial data. Cabozantinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases, including MET, VEGFR2, and RET. Its mechanism of action involves inhibiting these kinases, which are involved in tumor growth, angiogenesis, and metastasis. Several clinical trials have investigated the efficacy of cabozantinib in HCC. The CheckMate 040 trial, published in 2016, demonstrated that cabozantinib significantly improved overall survival (OS) compared to sorafenib in patients with advanced HCC. The trial showed that cabozantinib reduced the risk of disease progression or death by 34% compared to sorafenib. Additionally, the CheckMate 403 trial, published in 2018, evaluated the efficacy of cabozantinib in patients with HCC who had previously received sorafenib. The trial showed that cabozantinib improved OS and reduced the risk of disease progression or death compared to sorafenib. Based on these clinical trial results, cabozantinib has been approved by the FDA for the treatment of advanced HCC in patients with Child-Pugh A or B liver function, and in combination with bevacizumab and nivolumab for the first-line treatment of advanced HCC. Therefore, based on the available evidence, cabozantinib is effective for the treatment of Hepatocellular Carcinoma.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 9.519134759902954
}